Adding pembrolizumab to docetaxel did not significantly improve outcomes in previously treated patients with mCRPC.

The radiopharmaceutical lutetium 177 can be used after radium 223 to treat metastatic castration-resistant prostate cancer.

Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease who are eligible to receive the drug.

Even among patients with prostate cancer liver metastasis who have a poor prognosis, elevated ctDNA fraction and tumor suppressor gene loss differentiate survival.

Janux Therapeutics' lead drug, JANX007, shows promising prostate cancer results with no serious side effects. Find out why ...

Bayer today showcased significant advancements in its pharmaceutical growth strategy and pipeline at its recent annual Pharma ...

Explore JANX's promising early data in prostate cancer immunotherapy. Understand market challenges, buyout rumors, and ...

Guidelines created by a multi-disciplinary panel of specialists focus on implementation of novel treatments and technologies for which level 1 evidence is lacking.

The Medical Oncology Association of Southern California (MOASC) presented the highly anticipated 2025 Cary Presant, MD Young ...

"2025 is set to be a landmark year for Bayer Pharmaceuticals. We are bringing a number of groundbreaking products and our ...